Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?

La Revue de médecine interne
C de MoreuilA Delluc

Abstract

Multiple myeloma is a malignant plasma cells dyscrasia that mainly affects patients older than 65 years. These patients are at a higher risk for venous thromboembolism (VTE) because of cancer status, intrinsic risk factors, and exposure to prothrombotic therapies. The risk for VTE appears higher during the first months of myeloma treatment and decreases over time. Exposure to immunomodulatory drugs (IMIDs) such as thalidomide or lenalidomide in association with high doses of dexamethasone or anthracyclin-based chemotherapy is associated with a four-fold increased risk for VTE. Low-dose aspirin, preventive-dose of low molecular weight heparin (LMWH) or vitamin K antagonists were tested for primary prevention of VTE in myeloma patients receiving chemotherapy. The International Myeloma Working Group (IMWG) suggests stratifying VTE risk to decide which patients should receive VTE prevention. Then, the IMWG suggests giving low-dose aspirin to low VTE risk patients and LMWH or vitamin K antagonists to patients at high risk for VTE. For daily practice, it seems reasonable to start preventive doses of LMWH for 3 to 6 months in ambulatory myeloma patients receiving combined therapy with IMID and in all myeloma patients admitted to hospi...Continue Reading

References

Oct 6, 1999·American Journal of Hematology·Z YasinJ Palascak
Feb 22, 2002·The New England Journal of Medicine·Robert A KyleL Joseph Melton
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Nicholas MitsiadesKenneth C Anderson
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donna WeberRaymond Alexanian
Jul 31, 2003·Seminars in Thrombosis and Hemostasis·Maurizio ZangariGuido Tricot
Nov 25, 2003·Seminars in Thrombosis and Hemostasis·Jayesh Mehta, Seema Singhal
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S SallahN P Nguyen
May 12, 2006·The New England Journal of Medicine·Robert KnightJerome B Zeldis
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
Feb 19, 2008·Cancer·Smitha Patiyil MenonAntonio Palumbo
Apr 3, 2008·Cancer Treatment Reviews·Lisa K HicksUNKNOWN Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alok A Khorana, Gregory C Connolly
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alok A KhoranaGary H Lyman
Apr 14, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Noppacharn UaprasertNigel S Key
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Mar 18, 2015·La Revue de médecine interne·G DumasE Azoulay
Aug 11, 2015·La Revue de médecine interne·G FouquetX Leleu

❮ Previous
Next ❯

Citations

Dec 12, 2017·Clinical Case Reports·Badia BelarjSamira El Machtani Idrissi
Aug 20, 2019·International Journal of Laboratory Hematology·Hela BaccoucheNeila Ben Romdhane

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.